文献速递血管炎

贝那利珠单抗治疗嗜酸性肉芽肿性多血管炎:一项回顾性、多中心、队列研究

Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.
PubMed 文献 · Lancet Rheumatol · 2023-11-06

该欧洲多中心回顾性队列纳入121例复发难治性嗜酸性肉芽肿性多血管炎(EGPA)患者,接受贝那利珠单抗治疗。第3、6、12个月完全缓解率分别为12.4%、28.7%、46.4%,口服泼尼松剂量从基线10.0 mg/天降至第12个月2.5 mg/天,19例(16%)发生不良事件。

要点

  • 贝那利珠单抗治疗复发难治性EGPA,第12个月完全缓解率达46.4%(32/69)。
  • 口服泼尼松剂量从基线10.0 mg/天降至第12个月2.5 mg/天(p<0.0001)。
  • 19例(16%)发生不良事件,16例(13%)停用贝那利珠单抗。

核心结论

  • 这些数据提示贝那利珠单抗在真实临床实践中可能是EGPA的有效治疗。
  • 需要进一步的临床试验来证实贝那利珠单抗在基线疾病活动度更高的患者中的疗效。

研究设计与样本

  • 本研究为回顾性、多中心、队列研究,纳入来自欧洲EGPA研究组6个国家(意大利、法国、英国、俄罗斯、西班牙和瑞士)28个转诊中心的EGPA患者。
  • 纳入2019年1月1日至2022年9月30日期间接受贝那利珠单抗任何线治疗的121例复发难治性EGPA患者,其中女性64例(53%)、男性57例(47%),开始贝那利珠单抗治疗时中位年龄54.1岁(IQR 44.2-62.2)。
  • 贝那利珠单抗采用嗜酸性哮喘获批剂量,随访12个月,评估完全缓解、部分缓解、活动性疾病表现、肺功能、糖皮质激素剂量变化及安全性结局。

主要发现

  • 完全缓解(BVAS为0且泼尼松剂量≤4 mg/天)在第3个月为15/121例(12.4%,95%CI 7.1-19.6),第6个月为25/87例(28.7%,95%CI 19.5-39.4),第12个月为32/69例(46.4%,95%CI 34.3-58.8)。
  • 部分缓解(BVAS为0且泼尼松剂量>4 mg/天)在第3个月额外有43例(35.5%,95%CI 27.0-44.8),第6个月有23例(26.4%,95%CI 17.6-37.0),第12个月有13例(18.8%,95%CI 10.4-30.1)。
  • BVAS从基线3.0(IQR 2.0-8.0)降至第3个月和第6个月0.0(0.0-2.0),第12个月0.0(0.0-1.0)。
  • 有系统性表现、活动性周围神经病变、耳鼻喉受累和肺部受累的患者比例下降,肺功能检查改善;6例患者在完全缓解后复发。
  • 口服泼尼松(或等效药物)剂量从基线10.0 mg/天(5.0-12.5)降至第3个月5.0 mg/天(3.6-8.5)(p<0.01)、第6个月5.0 mg/天(2.5-6.3)、第12个月2.5 mg/天(0.0-5.0)(p<0.0001);19/121例(16%)发生不良事件,16例(13%)停用贝那利珠单抗。

关键数值与推荐

  • 完全缓解定义为无疾病活动(BVAS为0)且泼尼松剂量≤4 mg/天;部分缓解定义为BVAS为0且泼尼松剂量>4 mg/天。

临床怎么用

  • 原文结论提示贝那利珠单抗在真实临床实践中可能是EGPA的有效治疗,并指出需要进一步临床试验证实其在高基线疾病活动度患者中的疗效。

局限性

  • 原文指出需要进一步的临床试验来证实贝那利珠单抗在基线疾病活动度更高的患者中的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort of patients with EGPA. METHODS: This retrospective cohort study included patients with EGPA from 28 European referral centres of the European EGPA Study Group across six countries (Italy, France, UK, Russia, Spain, and Switzerland) who received benralizumab as any line of treatment between Jan 1, 2019, and Sep 30, 2022. We assessed the rates of complete response, defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] of 0) and a prednisone dose of up to 4 mg/day, in contrast to partial response, defined as a BVAS of 0 and a prednisone dose greater than 4 mg/day. Active disease manifestations, pulmonary function, variation in glucocorticoid dose, and safety outcomes were also assessed over a 12-month follow-up. FINDINGS: 121 patients with relapsing-refractory EGPA treated with benralizumab at the dose approved for eosinophilic asthma were included (64 [53%] women and 57 [47%] men; median age at the time of beginning benralizumab treatment 54·1 years [IQR 44·2-62·2]). Complete response was reported in 15 (12·4%, 95% CI 7·1-19·6) of 121 patients at month 3, 25 (28·7%, 19·5-39·4) of 87 patients at month 6, and 32 (46·4%, 34·3-58·8) of 69 patients at month 12; partial response was observed in an additional 43 (35·5%, 27·0-44·8) patients at month 3, 23 (26·4%, 17·6-37·0) at month 6, and 13 (18·8%, 10·4-30·1) at month 12. BVAS dropped from 3·0 (IQR 2·0-8·0) at baseline to 0·0 (0·0-2·0) at months 3 and 6, and to 0·0 (0·0-1·0) at month 12. The proportion of patients with systemic manifestations, active peripheral neurological disease, ear, nose, and throat involvement, and pulmonary involvement decreased, with an improvement in lung function tests. Six patients relapsed after having a complete response. The oral prednisone (or equivalent) dose decreased from 10·0 mg/day (5·0-12·5) at baseline to 5·0 mg/day (3·6-8·5) at month 3 (p<0·01), to 5·0 mg/day (2·5-6·3) at month 6, and to 2·5 mg/day (0·0-5·0) at month 12 (p<0·0001). 19 (16%) of 121 patients had adverse events and 16 (13%) discontinued benralizumab. INTERPRETATION: These data suggest that benralizumab could be an effective treatment for EGPA in real-life clinical practice. Further clinical trials are required to confirm the efficacy of benralizumab in patients with a higher baseline disease activity. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bettiol A, Urban ML, Padoan R, et al. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study. Lancet Rheumatol. 2023. PMID: 38251561. doi:10.1016/S2665-9913(23)00243-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。